Skip to content

Nasdaq · CIK 0002007919

INBX Inhibrx Biosciences, Inc.

Insider trading from SEC Form 4. Last filing 14 d ago. Close $95.01 on Oct 9, 2026, +235% from the 52-week low and -33% from the high.

Last 90 days

Net insider value
+$5.2M
more bought than sold
Buys
6
$5.5M by 3 insiders
Sells
2
$279k by 1 insider
Insiders on file
8
with a Form 4 at this company

Price and insider trades, last year

INBXOct 9, 2026 · close 95.01

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Inhibrx Biosciences, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
63NotableMark Lappe
Chief Executive Officer
buy
$999k
10,000 shares
+1%-
46ModerateJon Faiz Kayyem
director
buy
$500k
5,000 shares
+1%-
53ModerateJon Faiz Kayyem
director
buy
$500k
5,000 shares
+1%-
31WeakKimberly Manhard
director
sell
$164k
1,500 shares
-17%-
30WeakKimberly Manhard
director
sell
$115k
1,000 shares
-10%-
44ModerateDouglas Forsyth
director
buy
$287k
2,500 shares
+1%-
65NotableMark Lappe
Chief Executive Officer
buy
$2.6M
25,000 shares
+4%-
49ModerateJon Faiz Kayyem
director
buy
$568k
5,000 shares
+1%-
42ModerateViking Global Investors LP
owner
sell
$11M
350,000 shares
-22%+209% from low-6% from high
50ModerateJon Faiz Kayyem
director
buy
$1.5M
107,186 shares
+660%-

Transactions

The last 41 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 25, 2026Mark Lappe
Chief Executive Officer
POpen-market purchase
Common Stockindirect: By the Lappe Family Trust
+3,324$98.87$329k733,87214 d ago
Sep 25, 2026Mark Lappe
Chief Executive Officer
POpen-market purchase
Common Stockindirect: By the Lappe Family Trust
+2,176$99.60$217k736,04814 d ago
Sep 28, 2026Mark Lappe
Chief Executive Officer
POpen-market purchase
Common Stockindirect: By the Lappe Family Trust
+1,500$98.88$148k737,54814 d ago
Sep 28, 2026Mark Lappe
Chief Executive Officer
POpen-market purchase
Common Stockindirect: By the Lappe Family Trust
+3,000$101.70$305k740,54814 d ago
Sep 23, 2026Jon Faiz Kayyem
director
POpen-market purchase
Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust
+5,000$100.00$500k434,36019 d ago
Jun 3, 2026Kimberly Manhard
director
AGrant or award
Stock Option (right to buy)derivative
+10,000$0.00$010,00024 d ago
Jun 3, 2026Kristiina Vuori MD
director
AGrant or award
Stock Option (right to buy)derivative
+10,000$0.00$010,00024 d ago
Jun 3, 2026Jon Faiz Kayyem
director
AGrant or award
Stock Option (right to buy)derivative
+10,000$0.00$010,00024 d ago
Jun 3, 2026Douglas Forsyth
director
AGrant or award
Stock Option (right to buy)derivative
+10,000$0.00$010,00024 d ago
Sep 16, 2026Jon Faiz Kayyem
director
POpen-market purchase
Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust
+5,000$100.00$500k429,36025 d ago
Sep 11, 2026Kimberly Manhard
director
SOpen-market sale
Common Stockindirect: Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012
-500$111.78$56k8,50027 d ago
Sep 14, 2026Kimberly Manhard
director
SOpen-market sale
Common Stockindirect: Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012
-500$110.26$55k8,00027 d ago
Sep 15, 2026Kimberly Manhard
director
SOpen-market sale
Common Stockindirect: Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012
-500$105.05$53k7,50027 d ago
Sep 8, 2026Kimberly Manhard
director
SOpen-market sale
Common Stockindirect: Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012
-500$115.14$58k9,50032 d ago
Sep 9, 2026Kimberly Manhard
director
SOpen-market sale
Common Stockindirect: Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012
-500$115.80$58k9,00032 d ago
Sep 8, 2026Jon Faiz Kayyem
director
POpen-market purchase
Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust
+5,000$113.52$568k424,36034 d ago
Sep 8, 2026Mark Lappe
Chief Executive Officer
POpen-market purchase
Common Stockindirect: By the Lappe Family Trust
+5,895$99.29$585k711,44334 d ago
Sep 8, 2026Douglas Forsyth
director
POpen-market purchase
Common Stockindirect: By the Forsyth Family Trust Dated July 20, 2001
+2,500$114.65$287k227,06434 d ago
Sep 8, 2026Mark Lappe
Chief Executive Officer
POpen-market purchase
Common Stockindirect: By the Lappe Family Trust
+6,605$100.64$665k718,04834 d ago
Sep 8, 2026Mark Lappe
Chief Executive Officer
POpen-market purchase
Common Stockindirect: By the Lappe Family Trust
+1,100$107.12$118k719,14834 d ago
Sep 8, 2026Mark Lappe
Chief Executive Officer
POpen-market purchase
Common Stockindirect: By the Lappe Family Trust
+500$108.24$54k719,64834 d ago
Sep 8, 2026Mark Lappe
Chief Executive Officer
POpen-market purchase
Common Stockindirect: By the Lappe Family Trust
+1,219$111.88$136k720,86734 d ago
Sep 8, 2026Mark Lappe
Chief Executive Officer
POpen-market purchase
Common Stockindirect: By the Lappe Family Trust
+9,681$112.28$1.1M730,54834 d ago
Oct 7, 2025Viking Global Investors LP
owner
SOpen-market sale
Common Stockindirect: See Explanation of Responses
-308,643$32.25$10.0M1,267,823Oct 9, 2025
Oct 7, 2025Viking Global Investors LP
owner
SOpen-market sale
Common Stockindirect: See Explanation of Responses
-16,315$32.25$526k67,018Oct 9, 2025
Oct 7, 2025Viking Global Investors LP
owner
SOpen-market sale
Common Stockindirect: See Explanation of Responses
-25,042$32.25$808k102,864Oct 9, 2025
May 28, 2025Douglas Forsyth
director
AGrant or award
Stock Option (right to buy)derivative
+15,000$0.00$015,000May 29, 2025
May 28, 2025Jon Faiz Kayyem
director
AGrant or award
Stock Option (right to buy)derivative
+15,000$0.00$015,000May 29, 2025
May 28, 2025Kristiina Vuori MD
director
AGrant or award
Stock Option (right to buy)derivative
+15,000$0.00$015,000May 29, 2025
May 28, 2025Kimberly Manhard
director
AGrant or award
Stock Option (right to buy)derivative
+15,000$0.00$015,000May 29, 2025
Apr 1, 2025Kelly Deck
Chief Financial Officer
AGrant or award
Stock Option (right to buy)derivative
+15,000$0.00$015,000Apr 2, 2025
Apr 1, 2025David Matly
President
AGrant or award
Stock Option (right to buy)derivative
+50,000$0.00$050,000Apr 2, 2025
Mar 27, 2025Jon Faiz Kayyem
director
GGift
Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust
-90,000$0.00$0419,360Mar 28, 2025
Dec 16, 2024Jon Faiz Kayyem
director
GGift
Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust
-500,000$0.00$0509,360Dec 17, 2024
Dec 16, 2024Jon Faiz Kayyem
director
GGift
Common Stockindirect: By Jon Faiz Kayyem Revocable Trust
+250,000$0.00$0250,000Dec 17, 2024
Dec 16, 2024Jon Faiz Kayyem
director
GGift
Common Stockindirect: By Paige Gates-Kayyem Revocable Trust
+250,000$0.00$0250,000Dec 17, 2024
Dec 6, 2024Jon Faiz Kayyem
director
GGift
Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust
-52,000$0.00$01,009,360Dec 6, 2024
Nov 19, 2024Jon Faiz Kayyem
director
POpen-market purchase
Common Stockindirect: By Child A
+34,843$14.23$496k51,093Nov 22, 2024
Nov 19, 2024Jon Faiz Kayyem
director
POpen-market purchase
Common Stockindirect: By Child B
+34,843$14.23$496k51,093Nov 22, 2024
Nov 20, 2024Jon Faiz Kayyem
director
POpen-market purchase
Common Stockindirect: By Child A
+18,750$14.19$266k69,843Nov 22, 2024
Nov 20, 2024Jon Faiz Kayyem
director
POpen-market purchase
Common Stockindirect: By Child B
+18,750$14.19$266k69,843Nov 22, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

INBX insider trading: Inhibrx Biosciences, Inc. | InsiderTell